Key result
SGLT-2 inhibitors were associated with a lower reporting rate of atrial fibrillation compared to other glucose-lowering medications.
Why the study?
SGLT2i reduce heart failure risk and new data indicate they can prevent AF, prompting evaluation of the association between SGLT2i and AF in real-world adverse event reports.
Observational (n=704,129)
Answers are grounded in this paper and cite their sources.
Supports lower AF reporting with SGLT2 inhibitors in pharmacovigilance data; leaves open confirmation in prospective trials.
BACKGROUND: Sodium glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of heart failure and new data show they can prevent atrial fibrillation (AF). We examined the association between SGLT2i and AF in the Food and Drug Administration adverse event reporting system (FAERS). METHODS: We mined the FAERS from 2014q1 to 2019q4 to compare AF reporting for SGLT-2 i versus reports for other glucose lowering medications (ATC10 class). Several exclusions were sequentially applied for: concomitant medications; diabetes, cardiovascular or renal disease indication; reports for competing adverse events (genitourinary tract infections, ketoacidosis, Fournier's gangrene, amputation). We provide descriptive statistics and calculated proportional reporting ratios (PRR). RESULTS: There were 62,098 adverse event reports for SGLT2i and 642,031 reports for other ATC10 drugs. The reporting of AF was significantly lower with SGLT2i than with other ATC10 drugs (4.8 versus 8.7/1000; p < 0.001) with a PRR of 0.55 (0.49-0.62). Results did not change substantially after excluding reports listing insulin (PRR 0.49) or anti-arrhythmics (PRR 0.59) as suspect or concomitant drugs, excluding reports with indications for cardiovascular disease (PRR 0.49) or renal disease (PRR 0.55), and those filed for competing adverse events (PRR 0.63). Results were always statistically significant whether the diabetes indication was specified. Negative and positive controls confirmed internal validity of the database. CONCLUSIONS: In a large pharmacovigilance database, AF was robustly and consistently reported more frequently for diabetes medications other than SGLT2i. This finding complements available evidence from trials supporting a protective role of SGLT2i against the occurrence of AF.
No takes yet. Share an insight, caveat, or question.
Bonora et al. (2021) conducted an observational in Adverse events in patients taking glucose-lowering medications (n=704,129). SGLT-2 inhibitors vs. Other glucose-lowering medications (ATC A10 class) was evaluated on Reporting of atrial fibrillation (AF) (PRR 0.55, 95% CI 0.49-0.62, p=<0.001). SGLT-2 inhibitors were associated with a lower reporting rate of atrial fibrillation compared to other glucose-lowering medications.
Synapse has enriched 10 related papers. Consider them for comparative context: